ABSTRACT Since the relationships between pulmonary function, exercise capacity, and functional state or quality of life are generally weak, a self report questionnaire has been developed to determine the effect of treatment on quality of life in clinical trials. One hundred patients with chronic airflow limitation were asked how their quality of life was affected by their illness, and how important their symptoms and limitations were. The most frequent and important items were used to construct a questionnaire evaluating four dimensions: dyspnoea, fatigue, emotional function, and the patient's feeling of control over the disease (mastery). Reproducibility, tested by repeated administration to patients in a stable condition, was excellent: the coefficient of variation was less than 12% for all four dimensions. Responsiveness (sensitivity to change) was tested by administering the questionnaire to 13 patients before and after optimisation of their drug treatment and to another 28 before and after participation in a respiratory rehabilitation programme. In both cases large, statistically significant improvements in all four dimensions were noted. Changes in questionnaire score were correlated with changes in spirometric values, exercise capacity, and patients' and physicians' global ratings. Thus it has been shown that the questionnaire is precise, valid, and responsive. It can therefore serve as a useful disease specific measure of quality of life for clinical trials.
The relationships between changes in symptomatic and functional state in patients with chronic lung disease and changes in conventional physiological indices are often weak.' 2 This is particularly true for interventions such as respiratory rehabilitation programmes, in which patients are taught to cope with their physiological limitations.36 Direct measurement of the impact on patients' lives is therefore necessary to assess whether interventions are of benefit. Questionnaires that have been developed for this purpose include the oxygen cost diagram7 and the baseline and transition dyspnoea indexes.8 These tools address patients' dyspnoea but do not focus on the many other aspects of their lives that are affected by the illness. The responsiveness (the ability to detect clinically important change, even if that change is small) of these questionnaires has not been established, and they have not been directly compared in the clinical trial setting.
We therefore developed a measure of quality of life for patients with chronic airflow limitation designed for use in clinical trials. The questionnaire, the Chronic Respiratory Disease Questionnaire, examines four aspects of patients' lives: dyspnoea, fatigue, emotional function, and mastery (the feeling of control over the disease and its effects). In this paper we describe the development of the questionnaire, and present data regarding its reproducibility, validity (the extent to which it measures what it is intended to measure), and responsiveness.
Methods and results

PRINCIPLES OF QUESTI'ONNAIRE DEVELOPMENT
The questionnaire was designed to meet the following criteria9: Patients are then asked to choose the five most important activities from among those they have listed. These items constitute the dyspnoea dimension for that patient for the duration of the study.
The Chronic Respiratory Disease Questionnaire Guyatt, Berman, Townsend, Pugsley, Chambers that emerged from this process contained 20 items, which were serially pretested to clarify issues of wording and presentation of items. Initial administration of the questionnaire takes a maximum of 30 minutes, and usually 15-25 minutes. Follow up administration takes a maximum of 20 minutes, and usually 10-15 minutes. The structure and content of the questionnaire are described in the appendix. Studies were then undertaken to clarify the reproducibility, responsiveness, and validity of the questionnaire.
REPRODUCIBILITY
A single interviewer administered the questionnaire to 25 patients with stable chronic airflow limitation (best FEV, less than 70% of predicted, FEV,/VC less than 0 7) six times at two week intervals. Mean scores were similar for all four dimensions at each administration; there were no clinically important or statistically significant trends toward either improvement or deterioration. The coefficient of variation (the within person standard deviation divided by the mean) was 6% for the dyspnoea dimension, 9% for both fatigue and emotional function, and 12% for mastery. These results compare favourably with most indices of functional state and respiratory function.22
RESPONSIVENESS
The questionnaire was administered to 13 patients with chronic lung disease whose respiratory physicians predicted improvement with institution or modification of treatment. The underlying conditions included chronic airflow limitation (11 patients) and pulmonary fibrosis (two patients). Treatments included bronchodilators and steroids. The questionnaire was administered at the time ofconsultation and at a follow up visit two to six weeks later. Despite only small improvements in spirometric values, scores on each of the four questionnaire dimensions were substantially better at follow up. The scores of all four dimensions, standardised on a 10 point scale (so that, for example, the score on the dyspnoea dimension, which has a maximum of 35, was divided by 3 5), are depicted in figure 1. In the second responsiveness study we administered our questionnaire, along with several other questionnaires (see below), to 28 patients with chronic airflow limitation entering our multidisciplinary inpatient respiratory rehabilitation programme. The questionnaire was repeated two weeks after discharge. Substantial improvement in scores occurred on all four dimensions (fig 2) .
COMPARISON WITH EXISTING MEASURES
A paired t test of the differences in score between admission to the rehabilitation programme and two functional state. Items were generated from statements about disease related problems of daily living made by 100 patients with chronic airflow limitation, randomly selected from those attending a chest clinic. This selection process ensures that questionnaire items concentrate on areas of dysfunction most important to patients with chronic airflow limitation. The questionnaire is administered directly to the patients. While existing disease specific measures focus on shortness of breath, our questionnaire includes other major aspects of dysfunction as well. The reproducibility of the questionnaire remains excellent over 12 weeks. The questionnaire proved as responsive as or more responsive than the two existing questionnaires with which it was compared. The highly significant differences detected in relatively small numbers of subjects suggest that this questionnaire is sufficiently responsive to detect differences in quality of life with sample sizes that can be achieved in single centre studies. We cannot say how much of the improvement observed in either the clinic or the rehabilitation populations was due to a specific effect of the intervention, and how much was a placebo effect. Since placebos do make people feel better, and the questionnaire measures how people feel, we would anticipate that the questionnaire would be responsive to placebo effects. Responsiveness to placebo effects also characterises other measurements of outcome used in clinical trials in chronic airflow limitation, including spirometry, walking tests, and laboratory exercise tests. The extent to which the questionnaire is able to detect specific treatment effects in a randomised control trial remains to be determined.
The results reported here require confirmation in the hands of other investigators. Nevertheless, we believe that the evidence we 
